29 May 2019 13:25
Results of the Vectura Annual General Meeting
All Shareholder Resolutions Passed
Chippenham, UK, 29 May 2019: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting (AGM) held today were duly passed on a poll, the results of which are set out below:
RESOLUTION | VOTESFOR | % | VOTESAGAINST | % | VOTESTOTAL | VOTESWITHHELD |
To receive the Company's Report and Accounts for the financial year ended 31 December 2018, including the independent auditor's report. | 517,998,445 | 100.00 | 4,508 | 0.00 | 518,002,953 | 469,421 |
To approve the Directors' Remuneration Report for the year ended 31 December 2018 (excluding the Directors' Remuneration Policy). | 483,282,866 | 94.56 | 27,808,998 | 5.44 | 511,091,864 | 7,381,219 |
To appoint Paul Fry as a Director of the Company. | 514,046,824 | 99.93 | 347,553 | 0.07 | 514,394,377 | 4,078,717 |
To appoint Anne Whitaker as a Director of the Company. | 514,339,705 | 99.99 | 62,129 | 0.01 | 514,401,834 | 4,069,450 |
To appoint Dr Kevin Matthews as a Director of the Company. | 514,350,219 | 99.99 | 53,220 | 0.01 | 514,403,439 | 4,069,645 |
To re-appoint Dr Per-Olof Andersson as a Director of the Company. | 513,861,175 | 99.89 | 546,425 | 0.11 | 514,407,600 | 4,065,384 |
To re-appoint Bruno Angelici as a Director of the Company. | 513,162,028 | 99.00 | 5,157,967 | 1.00 | 518,319,995 | 153,089 |
To re-appoint Dr Susan Foden as a Director of the Company. | 425,085,739 | 82.01 | 93,217,752 | 17.99 | 518,303,491 | 169,592 |
To re-appoint James Ward-Lilley as a Director of the Company. | 518,065,321 | 99.95 | 260,624 | 0.05 | 518,325,945 | 147,139 |
To re-appoint Neil Warner as a Director of the Company. | 514,314,164 | 99.98 | 93,697 | 0.02 | 514,407,861 | 4,065,223 |
To re-appoint Dr Thomas Werner as a Director of the Company. | 458,303,304 | 88.79 | 57,883,040 | 11.21 | 516,186,344 | 2,286,739 |
To re-appoint Juliet Thompson as a Director of the Company. | 472,531,745 | 95.86 | 20,428,966 | 4.14 | 492,960,711 | 25,512,373 |
To re-appoint KPMG LLP as the Company's auditor. | 518,284,988 | 99.98 | 106,552 | 0.02 | 518,391,540 | 81,544 |
To authorise the Audit Committee to determine the auditor's remuneration. | 518,404,496 | 99.99 | 59,423 | 0.01 | 518,463,919 | 9,165 |
To authorise political donations and expenditure. | 511,974,263 | 98.76 | 6,435,501 | 1.24 | 518,409,764 | 61,534 |
To authorise the Directors to allot shares in the Company pursuant to section 551 of the Companies Act 2006. | 506,231,970 | 97.64 | 12,224,364 | 2.36 | 518,456,334 | 16,750 |
To authorise the disapplication of pre-emption rights. | 514,360,381 | 99.96 | 181,300 | 0.04 | 514,541,681 | 3,931,403 |
To authorise the disapplication of pre-emption rights in relation to an acquisition or other capital investment. | 497,868,456 | 96.76 | 16,674,124 | 3.24 | 514,542,580 | 3,930,503 |
To authorise market purchases of the Company's own shares. | 507,007,955 | 97.81 | 11,347,841 | 2.19 | 518,355,796 | 117,287 |
To authorise the calling of any general meetings of the Company other than and not less than 14 clear days. | 511,686,911 | 98.69 | 6,783,009 | 1.31 | 518,469,920 | 3,164 |
- Ends -
For more information, please contact:
Vectura Group plc |
|
|
|
David Ginivan - VP Corporate Communications Elizabeth Knowles - VP Investor Relations | +44 (0)7471 352 720 +44 (0)7767 160 565
|
Consilium Strategic Communications | +44 (0)20 3709 5700 |
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley |
|
About Vectura
Vectura is an industry-leading inhaled product formulation, device design and development business offering a uniquely integrated inhaled drug delivery platform. We develop inhalation products to help patients suffering from airways diseases.
Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Bayer, Chiesi, Almirall, Dynavax and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated technology and skills, maximising value by enhancing the delivery and performance of inhaled products, and through the development of high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at www.vectura.com